CD274 and neoplasm: We find that sublethal doses of antimetabolites, pemetrexed and 5-fluorouracil (5-FU), can upregulate PD-L1 expression in NSCLC cells and modulate activities of TILs, priming a favorable tumor microenvironment for ICB therapy.